PTCH1 sirna

PTCH1 siRNA (Human)

Cat. Num. AAA8215487

• Gene Names: PTCH1; PTC; BCNS; HPE7; PTC1; PTCH; NBCCS; PTCH11
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PTCH1; PTCH1 siRNA (Human); PTCH; Protein patched homolog 1; PTC; PTC1; PTCH1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PTCH1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1447

• Applicable Applications for PTCH1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PTCH1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PTCH1 sirna

siRNA to inhibit PTCH1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 134254446
• NCBI GeneID: 5727
• NCBI Accession #: NP_000255.2
• NCBI GenBank Nucleotide #: NM_000264.3
• UniProt Accession #: Q13635; Q13463; Q5R1U7; Q5R1U9; Q5R1V0; Q5VZC0; Q5VZC2; Q86XG7; A3KBI9; E9PEJ8
• Molecular Weight: 144,356 Da
• NCBI Official Full Name: protein patched homolog 1 isoform L
• NCBI Official Synonym Full Names: patched 1
• NCBI Official Symbol: PTCH1
• NCBI Official Synonym Symbols: PTC; BCNS; HPE7; PTC1; PTCH; NBCCS; PTCH11
• NCBI Protein Information: protein patched homolog 1
• UniProt Protein Name: Protein patched homolog 1
• UniProt Gene Name: PTCH1
• UniProt Synonym Gene Names: PTCH; PTC; PTC1
• UniProt Entry Name: PTC1_HUMAN

NCBI Description

This gene encodes a member of the patched gene family. The encoded protein is the receptor for sonic hedgehog, a secreted molecule implicated in the formation of embryonic structures and in tumorigenesis, as well as the desert hedgehog and indian hedgehog proteins. This gene functions as a tumor suppressor. Mutations of this gene have been associated with basal cell nevus syndrome, esophageal squamous cell carcinoma, trichoepitheliomas, transitional cell carcinomas of the bladder, as well as holoprosencephaly. Alternative splicing results in multiple transcript variants encoding different isoforms. Additional splice variants have been described, but their full length sequences and biological validity cannot be determined currently. [provided by RefSeq, Jul 2008]

Uniprot Description

PTCH1: a multi-pass membrane protein member of the ?patched? family that acts as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). Associates with the smoothened protein (SMO) to transduce the hedgehog protein?s signal. Seems to have a tumor suppressor function, as inactivation of this protein is probably a necessary, if not sufficient step for tumorigenesis. Interacts with SNX17. Expressed in tumor cells but not in normal skin. In the embryo, found in all major target tissues of sonic hedgehog, such as the ventral neural tube, somites, and tissues surrounding the zone of polarizing activity of the limb bud. Defects in PTCH1 are the cause of basal cell nevus syndrome (BCNS), also known as Gorlin syndrome. BCNS is an autosomal dominant disease characterized by nevoid basal cell carcinomas and developmental abnormalities such as rib and craniofacial alterations, polydactyly, syndactyly, and spina bifida. In addition, the patients suffer from a multitude of tumors like basal cell carcinomas, fibromas of the ovaries and heart, cysts of the skin, jaws and mesentery, as well as medulloblastomas and meningiomas. PTCH1 defects is also the cause of holoprosencephaly, the most common structural anomaly of the brain, in which the developing forebrain fails to correctly separate into right and left hemispheres.

Protein type: Cell cycle regulation; Membrane protein, multi-pass; Tumor suppressor; Membrane protein, integral

Chromosomal Location of Human Ortholog: 9q22.3

Cellular Component: Golgi apparatus; intracellular membrane-bound organelle; perinuclear region of cytoplasm; postsynaptic density; plasma membrane; integral to membrane; midbody; caveola

Molecular Function: heparin binding; protein binding; cyclin binding; hedgehog receptor activity; cholesterol binding; protein complex binding; patched binding; smoothened binding

Biological Process: heart morphogenesis; hindlimb morphogenesis; epidermis development; regulation of mitotic cell cycle; negative regulation of transcription from RNA polymerase II promoter; glucose homeostasis; response to estradiol stimulus; response to chlorate; regulation of protein localization; negative regulation of osteoblast differentiation; negative regulation of epithelial cell proliferation; embryonic limb morphogenesis; response to drug; smoothened signaling pathway; negative regulation of multicellular organism growth; pharyngeal system development; response to retinoic acid; in utero embryonic development; negative regulation of transcription factor activity; neural tube patterning; keratinocyte proliferation; negative regulation of cell division; spinal cord motor neuron differentiation; limb morphogenesis; organ morphogenesis; dorsal/ventral pattern formation; ureteric bud branching; response to mechanical stimulus; neural plate pattern formation; negative regulation of smoothened signaling pathway; neural tube closure; embryonic organ development; protein processing; brain development; regulation of smoothened signaling pathway

Disease: Basal Cell Nevus Syndrome; Holoprosencephaly 7; Basal Cell Carcinoma, Susceptibility To, 1